Revance Therapeutics Inc (NASDAQ:RVNC)

27.82
Delayed Data
As of Sep 17
 +1.33 / +5.02%
Today’s Change
22.89
Today|||52-Week Range
33.83
-1.83%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$2.0B

Company Description

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Contact Information

Revance Therapeutics, Inc.
1222 Demonbreun Street
Nashville Tennessee 37203
P:(615) 724-7755
Investor Relations:
(626) 589-1007

Employees

Shareholders

Mutual fund holders49.63%
Other institutional29.50%
Individual stakeholders14.98%

Top Executives

Mark J. FoleyPresident, Chief Executive Officer & Director
Abhay JoshiCOO & President-Research & Development
Tobin C. SchilkeChief Financial Officer
Azita NejadSenior Vice President-Technical Operations
Roman G. RubioSenior Vice President-Clinical Development